Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
An Update on Allopurinol and Kidney Failure; New Trend for an Old Drug Publisher



Alirezaei A1 ; Argani H1 ; Asgharpour M2 ; Bahadorimonfared A3 ; Bakhtiyari M4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Clinical Research and Development Center at Shahid Modarres Hospital, Department of Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Nephrology, Rouhani Hospital of Medical Sciences, Babol, Iran
  3. 3. Department of Health and Community Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Department of Community Medicine, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
  5. 5. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Renal Injury Prevention Published:2017


Abstract

Allopurinol is an inhibitor of xanthine oxidase (XO) enzyme. This drug is a reducer of uric acid in the body and one of the golden drugs with worldwide administration. XO is an important biological source of free radical generation. Allopurinol as an antioxidant, has direct and indirect antioxidant activity on these free radicals such as hydroxyl radical and superoxide anion. The purpose of this paper is to determine the impact of allopurinol on some aspects of renal disturbances such as renal ischemia/reperfusion injury (IRI), nephrotoxicity and contrast-induced nephropathy (CIN). © 2017 The Author(s).